

Raja Mudad, M.D., F.A.C.P

DOB: May 18, 1965
Citizenship: U.S. Citizen



PROFESSIONAL ADDRESS

3850 Hollywood Blvd
Suite 1B
Hollywood, FL 33021
1475 NW 12th Avenue
Suite 3510, Miami FL 33136
Phone : (954) 251-8867
Fax : (954) 874-9175
Email : rmudad@med.miami.edu

Professional Appointments

- Assistant Professor of Medicine, University of Miami Health System, Sylvester Comprehensive Cancer Center, November 2013-present
- Cancer Cure, PA, Private Practice, Hollywood, FL, October 2012- October 2013
- Chairman, Tumor Board, Memorial Cancer Institute, Hollywood, FL., August 2006-December 2013.
- Vice-chair, Hematology/Oncology Department, Memorial Regional Hospital, Hollywood, FL., May 2012-present
- Associate Director, Memorial Cancer Institute, Hollywood, FL., August 2008-September 2012
- Co- Director, Thoracic Oncology Program, Memorial Cancer Institute, Hollywood, FL., July 2011-September 2012 (Co-Director, Dr. Luis Raez)
- Director, Thoracic Oncology Program, Memorial Cancer Institute, Hollywood, FL., July 1, 2006-2011
- Associate Section Chief, Hematology/Oncology Section, Tulane University School of Medicine, August 2001- 2006.
- Chief, Hematology/Oncology Section, New Orleans VA Medical Center, June 1996-2006.
- Director, Hematology/Oncology fellowship program, July 2001- 2006.
- Acting Chief, Hematology/Oncology Section, Tulane University School of Medicine, July 2001-August 2001.
- Associate Chief, Hematology/Oncology Section, Tulane University School of Medicine, November 1, 2000-June 2001.
- Associate Professor of Medicine, Hematology/Medical Oncology, Tulane University School of Medicine, July 2001- May 2006.

- Assistant Professor of Medicine, Hematology/Medical Oncology, Tulane University School of Medicine, June 1996-June 2001.
- Associate Director, Hematology/Oncology fellowship program, July 1996-June 2001.
- Associate in Medicine, Hematology/Medical Oncology, Tulane University School of Medicine, July 1995-May 1996.

Education and Training

| | |
|-----------------|---|
| Fellowship: | Hematology/Oncology, July 1992-June 1995 Duke University Medical Center Durham, NC 27710 |
| Residency: | Internal Medicine, July 1990-June 1992 Duke University Medical Center Durham, NC 27710 |
| Internship: | Internal Medicine, July 1989-June 1990 Duke University Medical Center Durham, NC 27710 |
| Medical School: | Doctor of Medicine, July 1985-June 1989 Distinction American University of Beirut Beirut, Lebanon |
| College: | Bachelor of Science, Biology, 1982-1985 High distinction American University of Beirut Beirut, Lebanon |

Specialty Board Status

- Board Certified in Internal Medicine, (ABIM) September 1992-2002
- Board Certified in Medical Oncology, (ABIM) November 1995-2015
- Board Certified in Hematology, (ABIM) November 1996-2016

Medical Licensure

- Florida, 2006-present
- Louisiana, 1995-2009
- North Carolina 1989-1995
- ECFMG Certificate, 1989
- Flex, 1990

Honors and Awards

- Patients' Choice Award, 2012
- Compassionate Doctor Recognition, 2011
- On-Time Doctor Award, 2009
(<http://www.vitals.com>)
- Physician of the year award, Memorial Cancer Institute, 2011
- Leadership Recognition Award, Inpatient Oncology Unit, Memorial Regional Hospital, Hollywood, FL, May 2010
- American Cancer Society spirit award recipient, 2004.
- C. Thorpe Ray Outstanding Faculty Teacher Award, Tulane University School of Medicine, June 2003
- Outstanding teaching award, Tulane University School of Medicine, June 1998
- Outstanding teaching award, Tulane University School of Medicine, June 1997
- Member of the Musser-Burch Honorary Society, Tulane University School of Medicine, January 1996
- Distinction, MD degree, American University of Beirut, June 1989
- High Distinction, BS degree, American University of Beirut, June 1985

Membership in Professional Organizations

- IASLC, Member 2012
- American College of Physicians, **Member** 1993-1998, **Fellow** 1998-
- American Society of Hematology, **Associate Member** 1993, **Member** 1996
- American Society of Clinical Oncology, Member 1997
- Southwest Oncology Group, Member 1995-2006
- Louisiana Oncology Society, 1996-1998

Membership in Committees

- Sylvester Clinical Trial Acceleration Grant review committee, January 2014-present
- Chairman, Tumor Board Conference, Memorial Regional Hospital, Hollywood, FL, 2006-December 2013.
- Member, Cancer Committee, Memorial Regional Hospital, 2006-2013
- Chairman, Cancer Committee, New Orleans VA Medical Center, 1996- 2006
- Member, Tulane Cancer Center steering committee, November 2000- May 2006
- Member, Hematology/Oncology Fellowship committee, Tulane University School of Medicine, July 1996- May 2006
- Member, Housestaff Hearing Committee, Residency Training Program, Tulane University School of Medicine, August 1996- May 2006
- Member of the Cancer Care Subgroup Committee, Department of Veterans Affairs, VISN 16, 1998
- Member, Ethics Committee, Tulane University Hospitals and Clinics, July 1999-June 2001.
- Member, Performance Improvement Council, Tulane University Hospitals and Clinics, July 2000-June 2001.

- Member, Lung committee and GU committee, Southwest Oncology Group, 1996-2006.

Selected Invited Lectures and Courses

- Oral Presentation, IASLC/ESMO First International Lung Cancer conference, Geneva, Switzerland, March 2008.
- Invited lecturer, “Targeted Cancer Therapy”, San Jose, Costa Rica, May 2003
- Invited lecturer, “Supportive care”, “Flow Cytometry”, “Lung Cancer”, Tegucigalpa, Honduras, April 2003.
- “Results of first Tulane Cancer Center study RM 98-1” Tulane Cancer center seminar series, January 31, 2002.
- “Complementary and Alternative Cancer Therapy: Can the Shark beat the Crab?” Medicine Grand Rounds, Tulane Medical School, June 13, 2001.
- Invited lecturer, Guatemalan Society of ENT surgery, “Role of chemotherapy in Head and Neck Cancer”, “Role of chemotherapy in organ preservation”, Guatemala City, Guatemala, March 7-11, 2001.
- Invited faculty, Journal Club, Thibodaux, LA “Lung Cancer”, December 2000.
- Invited lecturer, “Today’s options in Lung Cancer”, Tulane Cancer Center research seminar, July 2000.
- Invited lecturer, “Today’s options in Lung Cancer for the primary care physician” at the Family Practice Update, Tulane University School of Medicine, Sheraton Hotel, New Orleans LA, May 2000
- Director and moderator, Tulane Cancer Center Oncology Update 1999, “An update for the primary care physician”, April 30-May 2 1999, New Orleans, LA
- “An update on the treatment of lung cancer”, Tulane Cancer Center Oncology Update 1999, May 1999, New Orleans, LA
- “Lung Cancer” lecture for primary care physicians, Tulane University, March 1998
- “The role of Chemotherapy in Hormone-Refractory Prostate Cancer”, Tulane Cancer Center Oncology Update, October 4, 1997
- Director and moderator, Tulane Cancer Center Oncology Update, “An update on Prostate and Lung Cancer”, October 4-5, 1997, New Orleans, LA

Community Activities

- Lung Cancer support group host, Hollywood, FL, November 2012-present
- “Cancer and the LGBT community”, lecture at the Gay and Lesbian community center, Fort Lauderdale, FL (February 2009)
- Smoking prevention lectures for school children (8th graders) in the south Florida community (2006, 2007, 2008)
- Lung cancer support group, Gilda’s club, Fort Lauderdale, FL (2006-2009)

Research Experience

CLINICAL

- SWOG Young Investigator Training course, Seattle/San Antonio, March 2000

Investigator-initiated protocols

Co-investigator in clinical protocol “A phase II study for treatment with I-131 MIBG in patients with metastatic carcinoid”. Principal investigator Jon P. Gockerman, M.D. Duke University Medical Center, Durham, NC, 1993.

Principal investigator in clinical protocol “A pilot/phase II trial of high dose Tamoxifen (TAM) and Vincristine, Adriamycin, Dexamethasone (VAD) in patients with refractory multiple myeloma”. Tulane University Medical Center, New Orleans, LA, 1995. (Closed)

Principal investigator in clinical protocol “A phase II study of Taxol in patients with Kaposi’s sarcoma”. Tulane University Medical Center, New Orleans, LA, 1996-1999. (closed)

Co- investigator in clinical protocol “Blood sampling in clinical cancer research” for evaluation of BCL2 expression in patients with Lymphoma. Principal investigator I: Melanie Ehrlich, Ph.D., Tulane University Medical Center, New Orleans, LA, 1996.

Principal investigator in clinical protocol “A phase II study for the treatment of patients with hormone refractory metastatic prostate carcinoma with Mitoxantrone, Prednisone and Pamidronate” Tulane University Medical Center, New Orleans, LA, 1997-1999. (Closed)

Principal investigator in clinical protocol “Combined modality therapy for locally advanced non-small cell lung cancer with weekly Cisplatin, Docetaxel and Radiation: a phase I/II study” Tulane University Medical Center, New Orleans, LA, 1998. (Completed)

Principal investigator in clinical protocol “A phase II trial of adjuvant chemotherapy for high risk transitional cell carcinoma of the urothelium” Tulane University Medical Center, New Orleans, LA, 2001 (closed)

Study Chair, SWOG Protocol S0022: “ Phase II Trial of concurrent Cisplatin/Docetaxel and radiotherapy followed by consolidation Docetaxel in stage IIIB NSCLC”, activated March 2001, completed December 2002.

Senior Principal investigator in clinical protocol “Evaluation of Arsenic Trioxide in Combination with 5-Fluorouracil in Gastrointestinal Tract Tumors” PI: Bilal Ansari, M.D., Fellow 2003 (closed)

Co-chair, SWOG Protocol S0310: “A Phase II study of GVAX in bronchioalveolar carcinoma”, closed December 2004.

BASIC

Expression cloning of JMH blood group antigen through screening of a human cDNA library, characterization of various monoclonal and human antibodies to JMH, purification of JMH protein from red cells, investigation of JMH role in hematopoiesis. Director, Marilyn J. Telen, MD. Duke University Medical Center, Durham, NC. September 1993-June 1995.

The Role of p-38 Mitogen Activated Protein Kinase in radiation induced esophagitis and pneumonitis in mice. PI: Tyler Curiel, M.D. (proof of concept experiment prior to development of human trial). June 2002- May 2006.

GRANTS

Bristol-Myers Oncology Division, grant support for protocol: "A phase II study of Taxol in patients with Kaposi's sarcoma", \$28,000, January 1997-January 1999, Principal Investigator. (closed)

Immunex, grant support for protocol: "A phase II study for the treatment of patients with hormone refractory metastatic prostate carcinoma with Mitoxantrone, Prednisone and Pamidronate", \$25,000, May 1997-November 1999, Principal Investigator. (closed)

Rhone-Poulenc Rorer, grant support for protocol: "Combined modality therapy for locally advanced non-small cell lung cancer with weekly Cisplatin, Docetaxel and Radiation: a phase I/II study", \$110,000.00, May 1998-completion of study, Principal investigator. (Completed)

Amgen, grant support for protocol: "RM-002: A Phase II Trial of adjuvant chemotherapy for high-risk transitional cell carcinoma of the urothelium" \$60,000.00, Principal investigator (closed)

Bristol-Myers Oncology division: "RM-002: A Phase II Trial of adjuvant chemotherapy for high-risk transitional cell carcinoma of the urothelium" \$90,000.00, Principal investigator (closed)

CTI pharmaceuticals "BA 002: Arsenic Trioxide and 5FU in refractory GI malignancies" \$97,125.00, Principal investigator (closed)

Publications

Papers

Mudad R, Kane WH: DDAVP in acquired hemophilia A: Case report and review of the literature. *Am J Hematol 43:295-299,1993.*

Mudad R, Vredenburgh J, Paulson EK, Ross M, Meisenberg B, Hussein A, Peters WP: A radiologic syndrome after high dose chemotherapy and autologous bone marrow transplantation, with clinical and pathologic features of systemic candidiasis. *Cancer 74:1360-1366,1994.*

Mudad R, Hussein A, Peters WP: Guillain-Barre syndrome following autologous bone marrow transplantation. *Am J Clin Oncol (CCT) 18(2): 167-169, 1995.*

Mudad R, Rao N, Angelisova P, Horejsi V, Telen MJ: Evidence that CDw108 membrane protein bears the JMh blood group antigen. *Transfusion 35:566-570, 1995*

Mudad R, Rao N, Issitt PD, Roy RB, Combs MR, Telen MJ: JMh variants: Serological, clinical and biochemical analysis in two cases. *Transfusion 35:925-930, 1995.*

Mudad R, Telen MJ: Biological Functions of Blood Group Antigens. *Current Opinion in Hematology 3:473-479, 1996.*

Zhang XY, Safah H, **Mudad R**, Maher E, Krause J, Miller A, Ehrlich M: Frequency of BCL-2/JH translocations in peripheral blood of follicular lymphoma patients. *American Journal of Hematology 55:205-207, 1997.*

Mahmood T, **Mudad R**: A case report of carcinoid syndrome with unknown primary. *Am J Clin Oncol, Aug;22(4): 384-386, 1999.*

Mahmood T, **Mudad R**: Pulmonary toxicity secondary to Procarbazine. *Am J Clin Oncol. Apr;25(2):187-188, 2002.*

Reviewed In: *Infectious Diseases Review Series, Issue 2:12-13, 2003* by C.A.T. Bremer, T. Mahmood, R. Mudad.

Bremer CA, Lastrapes A, Alper AB, **Mudad R**: Interferon alpha-induced focal segmental glomerulosclerosis in chronic myelogenous leukemia: A case report and review of the literature. *Am J Clin Oncol. Jun; 26(3):262-4, 2003.*

Mudad R, Ramsey M, Kovitz K, Curiel T, Hartz R, Nedzi LL, Weiner RS, Zakris EL: Concomitant weekly docetaxel, cisplatin and radiation therapy in locally advanced non-small cell lung cancer: A dose finding study. *Lung Cancer 39(2): 173-177, 2003.*

Raez LE, Santos ES, **Mudad R**, Podack ER. Clinical trials targeting lung cancer with active immunotherapy: the scope of vaccines. *Expert Rev Anticancer Ther. Aug;5(4):635-44, 2005*

Kahn MJ, **Mudad R**, Glotzbach JP, Owens DP Jr. Perspectives on the cancer death of a medical student. *Am J Hosp Palliat Care. Sep-Oct;22(5):393-6, 2005*

Book Chapters

Mudad R, Telen MJ: Autoimmune Hemolytic Anemia. *In: Conn's Current Therapy*, Rakel RE ed. W.B. Saunders Co. Philadelphia, PA., pp 340-344, 1996.

Mudad R: Lung Cancer, *In: Oklahoma Notes*, Biostat publishing Co., Oxnard, California, 2001.

Book Reviews

Mudad R. Review of: Scientific Writing: Easy When You Know How. Peat, Jennifer; Elliott, Elizabeth; Baur, Louise; Keena, Victoria. Doody's Review Service (online). Available: <http://www.doody.com>. (Accessed 11/02).

Abstracts

Vredenburg J, **Mudad R**, Paulson E, Ross M, Meisenberg B, Hussein A et al: Hepatic, splenic and renal candidiasis following high dose chemotherapy (HDC) and autologous bone marrow support. *Proc Am Soc Clin Oncol* 12:456 (abstract 1583),1993.

Mudad R, Rao N, Angelisova P, Horejsi V, Telen MJ: Evidence that CDw108 membrane protein bears the JMh blood group antigen. *Blood* 84 (10), suppl 1:237a (abstract 934), 1994. Presented, ASH meeting, Nashville TN, December 1994.

Mudad R, Levesque M, Vredenburg J, Telen MJ: Serum level of soluble CD44 (sCD44) in various malignancies. *Proc Am Soc Clin Oncol* 14:83 (abstract 36), 1995.

Issitt P, Combs M, **Mudad R**, Telen MJ: An anti-JMH causing in vivo red cell destruction. American Association of Blood Banks meeting, New Orleans, LA, 1995, (Poster presentation).

Mudad RA, Saux JE, Lastrapes AJ, Zaydan MAA: Evaluation of knowledge regarding cancer pain management among physicians in training: A pilot study. The 4th Annual VA Oncology Symposium, Washington, DC, October 1999, (Poster presentation).

Mudad RA, Cohen JE, Zakris E, Rozans M, Wynn R, Mai PL: Endobronchial brachytherapy in the management of obstructive lesions in Non-small cell lung carcinoma. The 4th Annual VA Oncology Symposium, Washington, DC, October 1999, (Poster presentation).

Chandramohan S, Rice J, **Mudad R**: Assessment of fatigue among veterans receiving chemotherapy for cancer. Proceedings of the American Society of Clinical Oncology, (19): 636a, 2000 (abstract 2511).

Mudad R, Zakris EL: Concomitant Docetaxel, Cisplatin and radiation (XRT) in the treatment of locally advanced non-small cell lung cancer (NSCLC): A phase I study. Proceedings of the American Society of Clinical Oncology, (19): 545a, 2000 (abstract 2146A).

Mudad R, Zakris EL: Maximal tolerated dose (MTD) of weekly Docetaxel with Cisplatin and radiation (XRT) in locally advanced non-small cell lung cancer (NSCLC): A phase I study. *Proceedings of the twelfth international congress on anti-cancer treatment, Feb 4, 2002, p119, Paris, France (oral presentation).*

Arias G, Bahan K, **Mudad R**: Why Do Veterans Not Receive Concomitant Chemoradiation For Locally Advanced NSCLC? A Retrospective Review. *The 7th Annual National VA Oncology Symposium, Alexandria, VA October 2-4, 2002 (Poster presentation).*

Mudad R, Zakris E, Kovitz K, Nedzi L. Non-malignant pericardial effusion as a long-term complication of combined modality therapy in non-small cell lung cancer (NSCLC). *Lung Cancer* Vol. 49, Suppl. 2 (2005), pS173, Abstract P220. *11th World Conference on Lung Cancer, Barcelona, Spain July 2005 (Poster presentation, outstanding poster)*

Higgins K, Gilbert J, **Mudad R**, Friedlander B, Fazekas M, Pou A, Wisdom G, Hanner S, Zakris E, Nedzi L: Variables associated with missed days of radiation in patients undergoing curative therapy for squamous cell carcinoma of the Head and Neck *Poster presentation at ASTRO 2005, Denver, Colorado.*

K. Higgins, J. Gilbert, **R. Mudad**, P. Friedlander, M. Fazekus, A. Pou, G. Wisdom, S. Hanner, E. Zakris and L. Nedzi: Socioeconomic Study of Mortality in Patients Undergoing Curative Radiation Therapy (RT) for Squamous Cell Carcinoma (SCC) of the Head and Neck. *Poster presentation at ESTRO 2005, Paris, France.*

Nedzi L, Walsh J. W, Weiner R, Payne B. R, Zakris E, Sanford R, Pearman T, Rosel P, **Mudad R**, Hall A, Weber J: Localized Therapy for Limited Metastatic Disease to the Brain: A Phase II Study of Surgery, Stereotactic Radiosurgery(SRS) and Stereotactic Radiotherapy(SRT) in Favorable Patients. *Poster Presentation at ISRS 2005, Brussels, Belgium.*

Mudad R, Block M, Forsyth P, Frankel C, Annesty D, Hussein A: Feasibility of lung cancer screening in a South Florida community. *Poster Presentation at the 1st European Lung cancer conference, Geneva, Switzerland, April 2008 (abstract # 99)*

Nedzi L, Walsh J, Weiner R, Zakris E, Sanford R, Pearman T, **Mudad R**, Timmerman, R, Mickey, B, Abdulrahman,R, Madden, C, Whitworth, A and Crockett, J: Localized Therapy for Limited Metastatic Disease to the Brain: A Phase II Study of Surgery, Stereotactic Radiosurgery and Stereotactic Radiotherapy in Favorable Patients: Final results. *Poster Presentation at ISRS 2011*

L.E. Raez, C. Sareli, **Raja Mudad**, F. Tarrazzi, Evelio Velis, S. Sundararaman, M. Block: Exploring Disparities in Health Care Outcomes in minority populations with Small (SCLC) and Non-small cell lung cancers (NSCLC). Abstract

presentation (Dr. Raez) at the World Lung Cancer Conference, Sydney, Australia,
October 2013.